Propelling Healthcare with Advanced Therapy Medicinal Products: A Policy Discussion.
European Union
Gene therapy
Gene transfer
Personalised healthcare
Personalised medicine
Policy
Quality of life
Tissue engineering
Vector design
Virus
Journal
Biomedicine hub
ISSN: 2296-6870
Titre abrégé: Biomed Hub
Pays: Switzerland
ID NLM: 101692630
Informations de publication
Date de publication:
Historique:
received:
31
07
2020
accepted:
17
09
2020
entrez:
14
5
2021
pubmed:
15
5
2021
medline:
15
5
2021
Statut:
epublish
Résumé
Recent advances in biomedicine are opening the door to new approaches, and treatment and prevention are being transformed by novel medicines based on genetic engineering, innovative cell-based therapies and tissue-engineered products, and combinations of a medical device with embedded cell or tissue components. These advanced therapy medicinal products (ATMPs) hold one of the keys to making a reality of genuinely personalised medicine. There are an estimated 450 companies across the globe working on the development of gene therapies and more than 1,000 clinical trials underway worldwide, and some 20-30 new ATMPs filings are expected in Europe annually over the next 5 years. But challenges confront the sector, complicating the translation from research into patient access. Scientific, clinical development and regulatory issues are compounded by limited experience with clinical and commercial use, limited manufacturing know-how, high costs, and difficulties in accessing development funding and investment. Pricing and reimbursement and market access issues are an additional challenge, particularly in Europe, where unfamiliarity with the technology and uncertainty over the use of real-world evidence induce caution among clinicians, health technology assessment bodies and payers. There is a need for a review of the suitability of the regulatory and market access framework for these products, focused development of data, public/private partnerships, and fuller collaboration governments, doctors, insurers, patients, and pharmaceutical companies. This paper makes specific recommendations for all stakeholders, ranging from early dialogue on potential products, linking of clinical data and patient registries or standardisation of control frameworks, to a comprehensive approach to evidence generation, assessment, pricing, and payment for ATMPs.
Identifiants
pubmed: 33987187
doi: 10.1159/000511678
pii: bmh-0005-0130
pmc: PMC8101061
doi:
Types de publication
Journal Article
Langues
eng
Pagination
130-152Informations de copyright
Copyright © 2020 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Eur J Health Econ. 2019 Apr;20(3):427-438
pubmed: 30229376
Front Pharmacol. 2019 Aug 30;10:921
pubmed: 31543814
Yale J Biol Med. 2017 Dec 19;90(4):683-693
pubmed: 29259533
Mol Ther Methods Clin Dev. 2018 Oct 11;11:121-130
pubmed: 30456217
J Mark Access Health Policy. 2017 Jan 3;5(1):1265293
pubmed: 28265348
J Biomed Biotechnol. 2003;2003(1):3-8
pubmed: 12686717
J Mark Access Health Policy. 2020 Jan 15;8(1):1715536
pubmed: 32082514
Mol Ther. 2012 Mar;20(3):471-2
pubmed: 22378026
Science. 2000 Apr 28;288(5466):669-72
pubmed: 10784449
Hum Gene Ther Clin Dev. 2017 Sep;28(3):126-135
pubmed: 28510497
Nat Biotechnol. 2012 Sep;30(9):807-9
pubmed: 22965030
Front Bioeng Biotechnol. 2018 Sep 21;6:130
pubmed: 30298129
Nat Biotechnol. 2019 Jul;37(7):697
pubmed: 31267108
Hum Gene Ther Clin Dev. 2014 Mar;25(1):1-6
pubmed: 24649836
Hum Gene Ther. 2017 Nov;28(11):951-953
pubmed: 28665213
Front Med (Lausanne). 2017 Oct 26;4:182
pubmed: 29124055
EMBO Mol Med. 2017 Jun;9(6):737-740
pubmed: 28396566
Lancet. 2012 Nov 17;380(9855):e10
pubmed: 23166921
Nat Med. 2019 Dec;25(12):1813-1814
pubmed: 31768067
Cell Med. 2019 Jan 22;11:2155179018822781
pubmed: 32634192
Nat Rev Drug Discov. 2016 May 3;15(5):299
pubmed: 27139988
Nat Biotechnol. 2012 Jul 10;30(7):588-93
pubmed: 22781675
Hum Gene Ther. 2016 Sep;27(9):653-5
pubmed: 27622542
Hum Gene Ther. 2014 Aug;25(8):740-6
pubmed: 24773182
Mol Ther Methods Clin Dev. 2019 Jan 29;13:205-232
pubmed: 30815512
Methods Enzymol. 2012;507:337-54
pubmed: 22365782